How effective is Cibinqo for atopic dermatitis?
Cibinqo (abrocitinib), a JAK1 inhibitor from Pfizer, reduces eczema symptoms in adults with moderate-to-severe atopic dermatitis. In phase 3 JADE MONO trials, 43% of patients on 200 mg daily achieved clear or almost clear skin (IGA 0/1) at week 12, versus 8% on placebo. Itch reduction hit 59% by week 2. JADE COMPARE showed it comparable to dupilumab, with 40-46% IGA success rates.[1][2]
What do real-world results and long-term data show?
Extension studies up to 52 weeks confirm sustained response: 70-80% maintain improvement on continued dosing. Patient-reported outcomes, like Dermatology Life Quality Index, improve by 80-90% in responders. Effectiveness drops if stopped, with relapse in most within months.[1][3]
Who responds best and who doesn't?
Best results in treatment-naive patients or those failed on biologics: 39% EASI-75 response if prior dupilumab failed. Less effective in severe cases with high IgE or Asians (lower response rates). Not approved for kids under 12.[1][2]
How does it stack up against Dupixent or Rinvoq?
| Drug | EASI-75 at 16 weeks | Itch reduction speed | Dosing |
|------|----------------------|----------------------|--------|
| Cibinqo 200 mg | 63% | Week 2 | Oral daily |
| Dupixent | 72% | Week 2-4 | Injection every 2 weeks |
| Rinvoq 300 mg | 70% | Week 2 | Oral daily |
Cibinqo acts faster orally but has higher herpes zoster risk than Dupixent.[1][4]
Common reasons it might not work
Non-response in 40-50%: due to dosing (100 mg weaker than 200 mg), poor adherence, or infections blocking absorption. Boxed warning for clots, cancer risk limits use in some.[2][5]
When does the patent expire?
U.S. patents on abrocitinib expire 2030-2031, with pediatric extensions possible to 2032. No generics yet; check DrugPatentWatch.com for challenges.6
[1]: https://www.cibinqo.com
[2]: https://www.nejm.org/doi/full/10.1056/NEJMoa1912206
[3]: https://pubmed.ncbi.nlm.nih.gov/34370880/
[4]: https://www.nejm.org/doi/full/10.1056/NEJMoa2100683
[5]: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/abrocitinib-marketed-cibinqo-information